Display options
Share it on

Mediators Inflamm. 1997;6(2):141-5. doi: 10.1080/09629359791848.

Mast cell amines and inosineinduced vasoconstriction in the rat hind limb.

Mediators of inflammation

A M Northover, B J Northover

Affiliations

  1. Department of Pharmaceutical Sciences School of Applied Sciences De Montfort University Leicester LE1 9BH UK.

PMID: 18472848 PMCID: PMC2365850 DOI: 10.1080/09629359791848

Abstract

Under certain circumstances injected inosine causes a net vasoconstrictive effect on the arterioles, which has been attributed to 5-hydroxytryptamine (5HT) released in response to adenosine type 3 (A(3)) receptor stimulation of mast cells residing in the adventitia. We have sought further evidence for this hypothesis using blood vessels of the rat hind limb perfused in vitro at constant rate with a gelatin-containing physiological salt solution. Injection of inosine (2.7 mg) caused a rise in perfusion pressure, which was only slightly increased by inclusion of N-nitro-L-arginine methyl ester (100 muM) in the perfusate. Inclusion in the perfusate of cyproheptadine (1 muM), compound 48 80 (1 mug ml), 8-phenyltheophylline (1 muM) or 8-cyclopentyl-1,3 dipropylxanthine (0.1 muM) greatly reduced the pressor response to inosine. The pressor effect of injected 5HT (400 mug) was abolished by pre-treatment with cyproheptadine, but not by pre-treatment with compound 48 80. These results suggest that the net pressor response to injected inosine was mainly the result of an A(1) receptor-mediated release of 5HT, most probably from mast cells. No evidence was found for an involvement of A(3) receptor stimulation.

References

  1. Physiol Rev. 1968 Oct;48(4):688-707 - PubMed
  2. Naunyn Schmiedebergs Arch Pharmacol. 1987 May;335(5):555-60 - PubMed
  3. Am J Physiol. 1969 Jan;216(1):56-62 - PubMed
  4. Acta Physiol Scand. 1989 Feb;135(2):95-105 - PubMed
  5. Int Arch Allergy Appl Immunol. 1965;26:362-72 - PubMed
  6. Am J Physiol. 1995 Oct;269(4 Pt 1):C821-30 - PubMed
  7. J Immunol. 1978 Mar;120(3):871-8 - PubMed
  8. Experientia. 1988 Aug 15;44(8):705-7 - PubMed
  9. Jpn J Pharmacol. 1979 Apr;29(2):243-51 - PubMed
  10. Eur J Pharmacol. 1981 Dec 3;76(2-3):275-7 - PubMed
  11. Br J Pharmacol Chemother. 1957 Dec;12(4):498-503 - PubMed
  12. Eur J Pharmacol. 1996 Mar 18;298(3):293-7 - PubMed
  13. Br J Pharmacol. 1986 Jan;87(1):233-42 - PubMed
  14. Am J Physiol. 1994 May;266(5 Pt 2):H2042-50 - PubMed
  15. J Physiol. 1993 Nov;471:767-86 - PubMed
  16. J Med Chem. 1994 Mar 4;37(5):636-46 - PubMed
  17. Biochem Pharmacol. 1984 Dec 1;33(23):3847-52 - PubMed
  18. Am J Physiol. 1960 Feb;198:322-6 - PubMed
  19. Br J Pharmacol. 1996 Jul;118(6):1509-17 - PubMed
  20. Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):55-9 - PubMed
  21. J Cardiovasc Pharmacol. 1994 Mar;23(3):387-94 - PubMed
  22. Med Pharmacol Exp Int J Exp Med. 1967;17(3):255-63 - PubMed
  23. J Med Chem. 1982 Mar;25(3):197-207 - PubMed
  24. Circ Res. 1996 Apr;78(4):627-34 - PubMed
  25. Mediators Inflamm. 1996;5(5):341-5 - PubMed
  26. Pharmacol Rev. 1991 Jun;43(2):109-42 - PubMed
  27. Am J Physiol. 1980 Apr;238(4):H569-74 - PubMed
  28. Life Sci. 1987 Nov 16;41(20):2295-302 - PubMed
  29. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59-63 - PubMed
  30. Br J Pharmacol. 1990 Nov;101(3):746-52 - PubMed
  31. Circ Res. 1971 Oct;29(4):375-84 - PubMed
  32. Am J Physiol. 1996 Feb;270(2 Pt 2):H560-6 - PubMed
  33. J Biol Chem. 1993 Aug 15;268(23):16887-90 - PubMed

Publication Types